NCT03625388 2023-09-22Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaHikma Pharmaceuticals LLCPhase 2 Completed56 enrolled